Author Archives: Diana Campelo Delgado

Double vision (diplopia) is common in people with Parkinson’s — affecting up to an estimated 30% of patients — and is linked to both motor and non‐motor disease symptoms, a new large-scale, longitudinal study has found. Parkinson’s patients with double vision were more likely to be older, non-white, female,…

Researchers have found a molecular link between Parkinson’s disease and melanoma, a type of skin cancer, in the form of protein clumps. Their study results were presented at the spring meeting of the American Chemical Society this week. A hallmark of Parkinson’s disease is the buildup of alpha-synuclein protein…

BlueRock Therapeutics has received permission from Health Canada to start a Phase 1 clinical trial evaluating DA01, an investigational cell therapy that aims to restore neurons lost to Parkinson’s disease. This clearance comes three months after the U.S. Food and Drug Administration (FDA) accepted the company’s request…

Aptinyx‘s Phase 2 clinical trial evaluating its investigational oral compound NYX-458 for the treatment of cognitive impairment and mild dementia associated with Parkinson’s disease is resuming patient screening after a temporary pause due to the COVID-19 pandemic. Recruitment is underway at multiple locations in the United States.

Magnetic nanoparticles may help restore brain function by directing nerve cell growth, a new study shows. Researchers believe this technology has therapeutic potential and may be used in the development of new treatments for Parkinson’s disease, The study, “Magnetic spatiotemporal control of SOS1 coupled nanoparticles for guided neurite growth in…

A protein fragment known as GPR37 is evident in the cerebrospinal fluid of people with Parkinson’s disease, and may be promising candidate as a biomarker for earlier diagnosis, scientists in Spain announced. This fragment at high levels was found to be specific to the cerebrospinal fluid (CSF; the liquid surrounding…

Forest Hills Lab announced plans to soon apply to the U.S. Food and Drug Administration (FDA) for permission to open a Phase 2 clinical trial evaluating the tolerability and efficacy of FHL-301 in people with Parkinson’s disease. FHL-301, or FHL CB-301, is reported to be a repurposed therapy…

The Parkinson’s Progression Markers Initiative (PPMI), a study sponsored by The Michael J. Fox Foundation, is recruiting people with known disease risk factors but no official Parkinson’s diagnosis, the foundation announced. Newly diagnosed patients, and healthy adults — those without any known Parkinson’s risk factors, who would…

Lockdown during the COVID-19 pandemic has affected speech and language therapy in patients with Parkinson’s disease, a survey in the United Kingdom shows. The survey was conducted by the Royal College of Speech and Language Therapists and asked patients to share their experiences from the past year. “There…

Cambridge Sleep Sciences and Parkinson’s Concierge have entered an agreement to tackle sleep problems in Parkinson’s disease. Sleep problems such as difficulty falling asleep, daytime sleepiness, and troubled dreams are among the most common non-motor symptoms of Parkinson’s disease. Sleep also can be indirectly affected by other…